| Emily Golueke, | |
|
3431 N 13th St, Sheboygan, WI 53083-2938 | |
| (920) 457-5046 | |
| Not Available |
| Full Name | Emily Golueke |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3431 N 13th St, Sheboygan, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225707011 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 5345-154 (Wisconsin) | Primary |
| Provider Name | Sundance Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1073912119 PECOS PAC ID: 7911815329 Enrollment ID: O20140917001161 |
News Archive
Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
As Congress prepares to leave Washington for the August recess, Democrats are worried the vacation will "kill momentum on health care reform," Politico reports.
Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.
Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful genetic mutations, as detailed in a study published today (Oct. 16) in Science Translational Medicine.
Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Golueke, 1655 N Mccarthy Rd Apt 2, Appleton, WI 54913-8461 Ph: (920) 321-8198 | Emily Golueke, 3431 N 13th St, Sheboygan, WI 53083-2938 Ph: (920) 457-5046 |
News Archive
Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
As Congress prepares to leave Washington for the August recess, Democrats are worried the vacation will "kill momentum on health care reform," Politico reports.
Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.
Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful genetic mutations, as detailed in a study published today (Oct. 16) in Science Translational Medicine.
Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.
› Verified 8 days ago
Mrs. Amy Laurell Krueger, MS-CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2508 Cooper Ave, Sheboygan, WI 53083 Phone: 920-889-5095 | |
Amy Marie Young, MS, CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3431 N 13th St, Sheboygan, WI 53083 Phone: 920-457-5046 Fax: 920-208-2713 | |
Mrs. Anneliese M Schneider, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3315 Behrens Pkwy, Sheboygan, WI 53081 Phone: 920-803-1617 Fax: 920-803-1622 | |
Sarah Luethy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1902 Mead Ave, Sheboygan, WI 53081 Phone: 920-458-8333 Fax: 920-458-3346 | |
Annie Cai, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3821 Kohler Memorial Dr Ste 102, Sheboygan, WI 53081 Phone: 920-208-9648 | |
Miss Charysse M Gregorash, MS-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3315 Behrens Pkwy, Sheboygan, WI 53081 Phone: 920-803-1617 Fax: 920-803-1622 | |
Rachel Ann Keene, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1125 N 13th St, Sheboygan, WI 53081 Phone: 920-803-1617 Fax: 920-803-1622 |